Granted Patent B2

US 12,419,865 · App. 17/299,270 · Granted Sep 23, 2025

Inventors: Eric Brown (Santee, CA); Vidyasagar Reddy Gantla (San Diego, CA); Nadezda Sokolova (San Diego, CA); Michael Bruno Plewe (San Diego, CA); Gregory Henkel (Carlsbad, CA); Kenneth McCormack (Oceanside, CA)

Assignee: Arisan Therapeutics Inc.

A61K31/4184A61K31/4192A61K31/437A61K31/519A61P31/14

Abstract

Claims (60)

1. A method of treating infections associated with viruses of the Arenaviridae enveloped virus family, or any virus expressing Arenavirus glycoproteins to mediate cell entry comprising administering a pharmaceutically effective dose of a compound of structural formula I:

or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, dilutant or vehicle there of wherein

A is N;

G is independently selected from CH or CD;

E is independently selected from CH or CD;

J is

R 2 is independently selected from —OR 3 , —R 4 , —NHR 10 , and —CONHR 10 ;

R 3 is independently selected from H, D, C 1 to C 6 alkyl, C 2 to C 6 alkenyl, —NHC(O)R 4 , —C(O)NHR 10 , and —C(O)R 10 , wherein each C 1 to C 6 alkyl is optionally substituted with D, halogen, —OH, —OR 4 , and —NHR 10 ;

R 4 is independently selected from C 1 to C 6 alkyl and (C 2 to C 9 ) cycloheteroalkyl optionally substituted with D, halogen, —OH, —OR 10 , and NHR 10 ;

R 5 is C 1 to C 6 alkyl, wherein C 1 to C 6 alkyl is optionally substituted with D;

R 6 is independently selected from halogen, —OR 3 , and R 4 ;

R 9 is independently selected from H, D, halogen, —OR 10 , and C 1 to C 6 alkyl;

R 10 is independently selected from H, D, C 1 to C 6 alkyl and C 2 to C 6 alkenyl;

with the proviso that the following compound is excluded:

2. The method of claim 1 wherein J is

R 2 is —OR 3 ; and R 6 is —OR 3 .

3. The method of claim 1 wherein E is CH or CD; R 2 is —OR 3 ; and R 6 is —OR 3 .

4. The method of claim 1 wherein A is N; R 2 is —OR 3 ; and R 6 is —OR 3 .

5. The method of claim 1 wherein R 6 is

6. The method of claim 1 wherein R 6 is

7. A method of treating infections associated with viruses of the Arenaviridae enveloped virus family, or any virus expressing Arenavirus glycoproteins to mediate cell entry, comprising administration of a therapeutically effective amount of a compound selected from the group consisting of:

8. The method of claim 7 , wherein the compound is selected from the group consisting of

9. A compound of structural formula I:

or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, dilutant or vehicle there of wherein

A is N;

G is independently selected from CH or CD;

E is independently selected from CH or CD;

J is

R 2 is independently selected from —OR 3 , —R 4 , —NHR 10 , and —CONHR 10 ;

R 3 is independently selected from H, D, C 1 to C 6 alkyl, C 2 to C 6 alkenyl, —NHC(O)R 4 , —C(O)NHR 10 , and —C(O)R 10 , wherein each C 1 to C 6 alkyl is optionally substituted with D, halogen, —OH, —OR 4 , and —NHR 10 ;

R 4 is independently selected from C 1 to C 6 alkyl and (C 2 to C 9 ) cycloheteroalkyl optionally substituted with D, halogen, —OH, —OR 10 , and NHR 10 ;

R 5 is C 1 to C 6 alkyl, wherein C 1 to C 6 alkyl is optionally substituted with D;

R 6 is independently selected from halogen, —OR 3 , and R 4 ;

R 9 is independently selected from H, D, halogen, —OR 10 , and C 1 to C 6 alkyl;

R 10 is independently selected from H, D, C 1 to C 6 alkyl and C 2 to C 6 alkenyl;

with the proviso that the following compound is excluded:

10. The compound of claim 9 wherein R 6 is

11. The compound of claim 9 wherein R 6 is

12. A compound selected from the group consisting of:

13. The compound of claim 12 , wherein the compound is selected from the group consisting of

14. The method of claim 1 wherein a pharmaceutically acceptable dose of the compound of claim 1 is administered with a pharmaceutically acceptable dose of at least one of the compounds selected from Ribavirin, polymerase inhibitors, Favipiravir, Triazavirin, small interfering RNAs (siRNAs), vaccines, monoclonal antibodies, and immunomodulators.

15. The compound of claim 9 wherein a therapeutic amount of the compound of claim 11 is administered with a therapeutic amount of the therapeutic agent selected from the group consisting of Ribavirin, polymerase inhibitors, Favipiravir, Triazavirin, small interfering RNAs (siRNAs), vaccines, monoclonal antibodies, or immunomodulators.

16. The compound of claim 13 , wherein the compound is

or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, dilutant or vehicle thereof.

17. The compound of claim 16 wherein a therapeutic amount of the compound of claim 16 is administered with a therapeutic amount of Favipiravir.

18. A compound of structural formula I:

or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, dilutant or vehicle there of wherein

A is N;

G is independently selected from CH or CD;

E is independently selected from CH or CD;

J is

R 2 is independently selected from —OR 3 and —R 4 ;

R 3 is independently selected from H, D, C 1 to C 6 alkyl, C 2 to C 6 alkenyl, —NHC(O)R 4 , —C(O)NHR 10 , and —C(O)R 10 , wherein each C 1 to C 6 alkyl is optionally substituted with D, halogen, —OH, —OR 4 , and —NHR 10 ;

R 4 is independently selected from C 1 to C 6 alkyl optionally substituted with D, —OH, and —OR 10 ;

R 5 is C 1 to C 6 alkyl, wherein C 1 to C 6 alkyl is optionally substituted with D;

R 6 is independently selected from halogen, —OR 3 , and R 4 ;

R 9 is independently selected from H, D, halogen, —OR 10 , and C 1 to C 6 alkyl;

R 10 is independently selected from H, D, C 1 to C 6 alkyl and C 2 to C 6 alkenyl;

with the proviso that the following compound is excluded:

19. The method of claim 8 , wherein the compound is

Assignments (1)

Continuity (2)

References Cited (293)